Search

Displaying results 161 - 170 of 12965 in total
  1. Drug

    Pancrelipase

    go.drugbank.com/drugs/DB00085
    ApprovedInvestigational

    Pancrelipase, in general, is composed of a mixture of pancreatic enzymes which include amylases, lipases, and proteases. These enzymes are extracted from porcine pancreatic glands. … [L2510] For further information on the components of this mixture please visit [DB11065], [DB11066] and [DB13147].

    Products: KREON 20000PH EU LI EI HKM, PANZYTRAT OK MA RE MICROTA
  2. Drug

    Darbepoetin alfa

    go.drugbank.com/drugs/DB00012
    ApprovedInvestigational

    Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.

    Products: ARANESP® 100µG SOLUCION INYECTABLE EN JERINGA PRELLENADA, ARANESP® 50 MCG SOLUCIÓN INYECTABLE EN JERINGA PRELLENADA
  3. Drug

    Gentian violet cation

    go.drugbank.com/drugs/DB00406
    Approved

    A dye that is a mixture of violet rosanilinis with antibacterial, antifungal, and anthelmintic properties.

    Mixtures: Kerr 100 Triple Dye Dispos-AProducts: De LA Cruz Gentian Violet, El Valle Gentian Violet
  4. Drug

    Fulvestrant

    go.drugbank.com/drugs/DB00947
    ApprovedInvestigational

    Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. … It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.

    Products: FULVESTRANT 250 MG/5ML SOLUCION INYECTABLE EN JERIGA PRECARGADA, FULTRANT ® 250MG/ 5ML SOLUCIÓN PARA INYECCIÓN EN JERINGA PRELLENADA
  5. Drug

    Trabectedin

    go.drugbank.com/drugs/DB05109
    ApprovedInvestigational

    Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. … Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer.

    Categories: Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexProducts: TRABECTEDINA EG, Trabectedin TEVA 0,25 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
  6. Drug

    Carteolol

    go.drugbank.com/drugs/DB00521
    Approved

    A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.

    Products: ARTEOPTIC LA, CARTEOL LP %1 UZUN ETKILI GOZ DAMLASI, 3 ML
  7. Drug

    Valproic acid

    go.drugbank.com/drugs/DB00313
    ApprovedInvestigational

    [A178051] It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. … It is currently a compound of interest in the field of oncology for its anti-proliferative effects and is the subject of many clinical trials in a variety of cancer types.

    Mixtures: Depakine Chronosphere 50 mg Retardgranulat in Beuteln, Depakine Chronosphere 50 mg Retardgranulat in BeutelnCategories: UGT1A1 Substrates with a Narrow Therapeutic Index, UGT1A3 Substrates with a Narrow Therapeutic Index
  8. Drug

    Guaifenesin

    go.drugbank.com/drugs/DB00874
    ApprovedInvestigationalVet approved

    After the negotiation between FDA and major manufacturers, a voluntary transition of labels for not using guaifenesin in children under the age of 4 years was endorsed by FDA in 2008 [F4525]. … Guaifenesin possesses a storied history, having been originally formally approved by the US FDA in 1952 and continues to be one of very few - if not perhaps the only drug that is readily available and

    Mixtures: Entex LA, Entex LAProducts: Siltussin SA, Compresso Ggf 95 Sa
  9. Drug

    Tetracaine

    go.drugbank.com/drugs/DB09085
    ApprovedInvestigationalVet approved

    Tetracaine is an ester local anaesthetic currently available in combination with lidocaine as a cream and patch.

    Products: NeuroMed LA, NeuroMed Topical Analgesic LA
  10. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    [A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. … Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.

    Products: Nucynta ER, TAPENTADOLO EG